Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.
The firm increased the number of shares it was offering after its stock price fell sharply this week.
The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
The Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, and reversed the 3 percent loss it saw in December.
Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
The Index also outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, all of which also showed double-digit percentage growth.
The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.
OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.
The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.
A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.